Compare VanEck Rare Earth/Strategic Metals (REMX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Rare Earth/Strategic Metals vs Vertex Pharmaceuticals Incorporated — how do they compare? VanEck Rare Earth/Strategic Metals trades at $60.97 (market cap $1.79B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 71.6× VanEck Rare Earth/Strategic Metals's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Rare Earth/Strategic Metals for 50 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| REMX | VRTX | |
|---|---|---|
Market Cap | $1.79B | $128.16B |
Volume | 1,233,740 | 806,603 |
Sector | Sector/Thematic | Health |
52-Week High | $109.53 | $557.96 |
52-Week Low | $60.58 | $407.37 |
Typical Hold Time | 50 Days | 120 Days |
Enterprise Value | — | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
REMX (VanEck Rare Earth and Strategic Metals ETF) is trading at $61.88, down 2.99% with a bearish technical signal. The ETF faces selling pressure across moving averages and oscillators, though RSI readings below 23 suggest potential oversold conditions. Recent news highlights increased institutional interest from Bank of America while the rare earth sector navigates geopolitical tensions and U.S. supply chain developments.
The ETF's high volatility (~50% annualized) and China-heavy exposure present significant risks, though strategic importance of rare earth metals for defense and technology offers long-term thematic appeal. Current technical weakness contrasts with fundamental tailwinds from U.S. supply chain initiatives, creating a contested investment case requiring careful risk assessment.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
